Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher...

|By:, SA News Editor

Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher John McCamant - who calls the firm one of the most exciting names in biotech. He highlights the company's B-cell lymphoma drug that is in phase 2 and landed a deal with a unit of Johnson & Johnson that includes a $150M upfront payment and a 50/50 profit/loss split worldwide.